Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion.

Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. (NYSE:PFE) for $1 billion on July 28, 2023. Alexion to acquire the assets for total consideration of up to $1 billion, plus tiered royalties on sales. Alexion plans to close the transaction in Q3 2023, subject to the satisfaction of closing conditions.

Centerview Partners LLC acted as financial advisor to Pfizer Inc. Mike Riella, Patrick Manchester, Jessica Milner, Gustavo Akkerman, and Sara Needles of Covington & Burling LLP acted as legal advisors to Alexion. Lowell Dashefsky, David Menchel, Laurie Abramowitz, Jennifer Perkins, Matthew Tabas and Niels Christian Ersbøll of Arnold & Porter acted as legal advisors to Pfizer.